RepliCel Retains Westwicke Partners as Investor Relations Counsel

RepliCel Retains Westwicke Partners as Investor Relations Counsel 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/04/13 -- RepliCel
Life Sciences Inc. (OTCBB:REPCF)(CNSX:RP), a clinical stage
biopharmaceutical company focused on the development of autologous
cell therapies, today announced that it has retained Westwicke
Partners as its investor relations agency to assist in the company's
communications with investors. Westwicke Partners provides strategic
investor relations and capital markets advisory services exclusively
to public and private companies in the healthcare sector.  
"Westwicke Partners' expertise, established relationships and
strategic counsel in investor relations and the biopharmaceutical
sector will add significant value to RepliCel's outreach efforts to
increase visibility within the financial and investor communities,"
stated David Hall, CEO of RepliCel. "We look forward to working with
the Westwicke team and to leveraging their experience as we continue
to advance our clinical development programs." 
About RepliCel Life Sciences 
RepliCel is a clinical stage biopharmaceutical company focused on
developing autologous cell therapies. RepliCel Hair-01 (RCH-01) is a
cellular treatment for androgenetic alopecia (pattern baldness).
Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South
Korea. RepliCel Tendon-01 (RCT-01) is a cell therapy for the
treatment of chronic tendon injuries. Both product candidates are
based on RepliCel's innovative technology which utilizes cells
isolated from a patient's own healthy hair follicles to address
specific cellular deficits. Phase II clinical trials, for both
programs, are planned for the later part of 2013. For additional
information please visit  
About Westwicke Partners 
Westwicke Partners provides strategic investor relations and capital
markets advisory services exclusively to healthcare companies. With
offices in Baltimore, San Francisco and San Diego, the firm works
with over 50 public and private companies across all subsectors of
healthcare. Services provided by Westwicke include corporate message
and positioning, investor presentation review, sell side relationship
building, buy side targeting, earnings call preparation, capital
markets advisory, pre-IPO planning and execution, and investor day
meetings. All of Westwicke's senior professionals have extensive Wall
Street experience as former sell side and buy side research analysts,
portfolio managers, investment bankers, institutional sales people,
and equity capital markets professionals. The firm works with its
clients to help position their story properly within the investment
community, raise their visibility on Wall Street, and develop
value-added strategies to build a quality, long-term shareholder base
and enhance equity market value. For additional information about
Westwicke please visit  
Notice Regarding Forward Looking Statements 
This press release contains projections and forward-looking
statements, as that term is defined under applicable securities laws.
Statements in this press release, which are not purely historical,
are forward-looking statements that relate to the approval and
commercialization of the Company's hair restoration process, the
Company's development of its Achilles tendon technology and the
expected commencement of the Company's Phase II clinical trial for
its tendon technology. These statements are only predictions and
involve known and unknown risks which may cause actual results and
the Company's plans and objectives to differ materially from those
expressed in the forward-looking information, including: negative
results from the Company's clinical trials; the effects of government
regulation on the Company's business; risks associated with the
Company's ability to obtain and protect rights to its intellectual
property; risks and uncertainties associated with the Company's
ability to raise additional capital; and other factors beyond the
Company's control. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity or
performance. Further, any forward-looking statement speaks only as of
the date on which such statement is made, and, except as required by
applicable law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence
of unanticipated events. New factors emerge from time to time, and it
is not possible for management to predict all of such factors and to
assess in advance the impact of such factors on the Company's
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statement. Readers should consult
all of the information set forth herein and should also refer to the
risk factor disclosure outlined in the Company's annual report on
Form 20-F for the fiscal year ended December 31, 2012 and other
periodic reports filed from time-to-time with the Securities and
Exchange Commission on Edgar at and with the British
Columbia Securities Commission on Sedar at
RepliCel Life Sciences
Tammey George
Director of Communications
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507 
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
(858) 356-5932
Press spacebar to pause and continue. Press esc to stop.